Effect of tamoxifen on steroid hormone receptors and creatine kinase activity in human endometrial carcinoma

Iacobelli, Stéfano; Scambia, Giovanni; Atlante, G; Landoni, Fabio; Sismondi, P; Vecchio, Fabio Maria

doi:10.1016/0277-5379(86)90349-4

Cited by 16 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a significantly higher positive coexpression of ER and PR in the CIN III group than in CIN III of the MIC group. As induction of PR is one of the best‐recognized responses to estrogen in target tissues ( 70,71 ) , we can hypothesize that in the MIC group, most of ER may have no or reduced functional activity. The finding that in all cases in the MIC group with coexpression of ER and PR, the ER staining was stronger and expressed in more cells than PR staining, which is not true for CIN III group, supports this idea.…”

Section: Discussionmentioning

confidence: 99%

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Fonseca-Moutinho¹,

Cruz

Carvalho

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

Abstract. Fonseca-Moutinho JA, Cruz E, Carvalho L, Prazeres HJM, de Lacerda MMP, da Silva DP, Mota F, de Oliveira CF. Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer 2004;14:911-920.There are no known biological markers or technologies to predict the natural history of an individual CIN III. The probability of progression is considered greater with the persistence of high-risk human papillomavirus (HPV) infection and age. p53 polymorphism has been associated with cervical carcinogenesis. Hormone-induced cervical cancer is mediated by estrogen receptor (ER) and progesterone receptor (PR). In cervical cancer, increased bcl-2 and Bax immunoreactivity is generally associated with a better prognosis. The purpose of this study was to evaluate the value of HPV 16 and HPV 18 typing and p53 codon polymorphism genotyping by polymerase chain reaction and ER, PR, bcl-2, and Bax expression by immunohistochemistry in predicting the CIN III clinical behavior of CIN III lesions. We studied the expression of these prognostic factors in the CIN III adjacent to squamous cell microinvasive carcinomas of the cervix (MIC) from 29 patients with FIGO stage IA1 cervical cancer and in 25 patients with CIN III and no documented focus of invasion. In the MIC group, only the CIN III was considered at least 2 mm away from the microinvasive complex. The ER, PR, bcl-2, and Bax immunoreactivity was scored as positive (>10% staining cells) and negative (<10% staining cells). No significant difference was observed between MIC and CIN III group concerning HPV infection and p53 polymorphism. The ER, PR, bcl-2, and Bax immunohistochemical expression was stronger and more frequent in the CIN III group. After multivariable analysis, coexpression of ER, PR, and bcl-2 was the only independent factor in defining low risk of progression for CIN III. Our study suggests that coexpression of ER, PR, and bcl-2 may be a useful tool in identifying the CIN III lesions with low risk of progression to cervical cancer.KEYWORDS: cervical microinvasive carcinoma, CIN III, immunohistochemistry, prognosis.Cervical cancer is one of the most frequent cancers in women, with an estimated worldwide incidence of about 371,000 new cases per year and an overall 5-year survival ranging from 44 to 66% for all clinical stages (1) .

show abstract

Section: Discussionmentioning

confidence: 99%

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Fonseca-Moutinho¹,

Cruz

Carvalho

et al. 2004

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Marshall and Senior [35] and Iacobelli et al [36] have reported that early and late uterine response to estrogen and TAM may be the result of different control systems such as, for example, intracytoplasmic EGF or creatinine kinase content.…”

Section: Discussionmentioning

confidence: 99%

Side Effects of Tamoxifen in Oophorectomized Rats

Kafkaslı¹,

Erdem²,

Müezzínoğlu³

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: Our objective was to evaluate the direct effect of tamoxifen citrate (TAM) on the endometrium, liver, breast tissue and the lipid profile in oophorectomized (OX) rats. Study Design: An experimental animal study. Material and Methods: Forty-one mature rats (33 OX) were randomly divided into four groups and received either TAM (0.4 or 0.8 mg/kg p.o.) therapy or placebo over 60 days as follows: (1) sham; (2) OX + TAM (0.4 mg/kg); (3) OX + TAM (0.8 mg/kg); (4) OX. All histological changes in the endometrium, liver and breast tissue were evaluated under the light microscope by comparing the TAM-treated groups with the OX and sham-operated groups. Blood total cholesterol and low-density lipoprotein cholesterol levels were also analyzed. Results: TAM-treated rats showed a significant reduction in body weight, blood cholesterol and low-density lipoprotein cholesterol levels, but the wet uterine weight was not affected. Estrogenic effects of TAM were not detected with either dosage on the endometrium. TAM-treated groups showed atrophic breast tissue. No histopathological changes were detected in the liver with TAM treatment. Conclusion: The data suggests that TAM may not act as an estrogen receptor agonist with the given dosage on the endometrium in OX rats. Two different doses of TAM do not cause histological changes in liver over 60 days of treatment.

show abstract

“…Estrogen and progesterone receptors were assayed in tumor cytosol prepared in buffer (10 mM Tris, pH7.4: 1.5mM EDTA) by the dextran-coated charcoal technique as described [7]. Results were expressed in fmoles/mg cytosol protein.…”

Section: Steroid Hormone Receptor Determinationmentioning

confidence: 99%

Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients

Iacobelli

Arno

Sismondi

et al. 1988

Breast Cancer Res Tr

View full text Add to dashboard Cite

An enzyme-linked immuno-absorbent assay has been developed for the detection of a circulating tumor-associated antigen, 90K, recognized by murine monoclonal antibody SP-2 (Iacobelli et al., Cancer Res 46: 3005-3010, 1986). This assay was found to be simple and reproducible. Using this method, 6% of 165 apparently healthy individuals and 15% of 91 patients with benign breast disease showed 90K levels above 1.7 units/ml. Approximately 50% of 129 patients with advanced breast cancer demonstrated serum antigen levels above 1.7 units/ml. All histological types of breast cancer were positive, and no association between the incidence of elevated 90K levels and other prognostic variables could be detected. The titers of 90K were significantly higher in sera from advanced-stage (3 and 4) patients than in those from patients with limited-stage (1 and 2) disease. Elevated 90K levels were also observed in patients with carcinomas of other sites, including gastrointestinal, gynecological, and lung tumors. By means of the immune blotting technique, the antigenic components carrying the determinants in serum and extracts of breast cancer cells have been identified. The levels of 90K did not correlate with those of CA 15-3 or CEA. The measurement of 90K in sera appears to be a useful adjunct to other available assays for the detection and monitoring of breast cancer and other malignant tumors.

show abstract

Effect of tamoxifen on steroid hormone receptors and creatine kinase activity in human endometrial carcinoma

Cited by 16 publications

References 17 publications

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III

Side Effects of Tamoxifen in Oophorectomized Rats

Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients

Contact Info

Product

Resources

About